- Home
- CNMD vs EWTX Comparison
CNMD vs EWTX Comparison
Compare CNMD & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNMD
- EWTX
- Stock Information
- Founded
- CNMD 1970
- EWTX 2017
- Country
- CNMD United States
- EWTX United States
- Employees
- CNMD N/A
- EWTX N/A
- Industry
- CNMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- CNMD Health Care
- EWTX Health Care
- Exchange
- CNMD Nasdaq
- EWTX Nasdaq
- Market Cap
- CNMD 1.7B
- EWTX 1.6B
- IPO Year
- CNMD 1987
- EWTX 2021
- Fundamental
- Price
- CNMD $45.58
- EWTX $16.23
- Analyst Decision
- CNMD Hold
- EWTX Buy
- Analyst Count
- CNMD 5
- EWTX 10
- Target Price
- CNMD $59.80
- EWTX $37.90
- AVG Volume (30 Days)
- CNMD 386.7K
- EWTX 974.3K
- Earning Date
- CNMD 11-05-2025
- EWTX 11-06-2025
- Dividend Yield
- CNMD 1.72%
- EWTX N/A
- EPS Growth
- CNMD 12.82
- EWTX N/A
- EPS
- CNMD 3.54
- EWTX N/A
- Revenue
- CNMD $1,326,244,000.00
- EWTX N/A
- Revenue This Year
- CNMD $6.73
- EWTX N/A
- Revenue Next Year
- CNMD $5.45
- EWTX N/A
- P/E Ratio
- CNMD $13.14
- EWTX N/A
- Revenue Growth
- CNMD 3.94
- EWTX N/A
- 52 Week Low
- CNMD $45.07
- EWTX $10.60
- 52 Week High
- CNMD $78.00
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- CNMD 35.68
- EWTX 58.05
- Support Level
- CNMD $45.28
- EWTX $14.94
- Resistance Level
- CNMD $48.44
- EWTX $15.84
- Average True Range (ATR)
- CNMD 1.56
- EWTX 0.99
- MACD
- CNMD -0.11
- EWTX 0.03
- Stochastic Oscillator
- CNMD 9.09
- EWTX 81.99
About CNMD CONMED Corporation
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.